We are live on ! Find out more
AVIR icon

Atea Pharmaceuticals
AVIR

119 hedge funds and large institutions have $171M invested in Atea Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 44 increasing their positions, 42 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

233% more call options, than puts

Call options by funds: $260K | Put options by funds: $78K

5% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 42

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.23% less ownership

Funds ownership: 68.4% → 68.17% (-0.23%)

11% less funds holding

Funds holding: 133 → 119 (-14)

20% less capital invested

Capital invested by funds: $213M → $171M (-$42.7M)

70% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 20

Holders
119
Holders Change
-14
Holders Change %
-10.53%
% of All Funds
1.89%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
6
Increased
44
Reduced
42
Closed
20
Calls
$260K
Puts
$78K
Net Calls
+$182K
Net Calls Change
+$88K

Top Buyers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
+$8.72M
2
SCM
Stonepine Capital Management
Oregon
+$3.29M
3
TCM
Tang Capital Management
California
+$1.95M
4
BlackRock
BlackRock
New York
+$1.64M
5
NM
Newtyn Management
New York
+$1.06M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$6.96M
2
CAM
Cormorant Asset Management
Massachusetts
-$5.79M
3
Citadel Advisors
Citadel Advisors
Florida
-$3.05M
4
First Trust Advisors
First Trust Advisors
Illinois
-$761K
5
Morgan Stanley
Morgan Stanley
New York
-$559K
Name Holding Trade Value Shares
Change 		Change in
Stake
GCP
26
GSA Capital Partners
United Kingdom
$835K +$280K +82,208 +42%
CM
27
CM Management
Florida
$825K +$85.1K +25,000 +10%
Morgan Stanley
28
Morgan Stanley
New York
$795K -$559K -164,404 -38%
Goldman Sachs
29
Goldman Sachs
New York
$783K -$152K -44,698 -15%
Susquehanna International Group
30
Susquehanna International Group
Pennsylvania
$654K -$297K -87,411 -29%
Invesco
31
Invesco
Georgia
$636K +$5.38K +1,581 +0.8%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$618K +$542K +159,300 +342%
DC
33
Diametric Capital
Massachusetts
$600K +$425K +125,000 +167%
AI
34
Auour Investments
Massachusetts
$535K – – –
RC
35
RBF Capital
California
$457K -$21.2K -6,233 -4%
CSS
36
Cubist Systematic Strategies
Connecticut
$417K +$334K +98,081 +239%
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$403K -$23K -6,747 -5%
AllianceBernstein
38
AllianceBernstein
Tennessee
$374K – – –
AI
39
Acuitas Investments
Washington
$370K -$10 -3 -0%
State of Wisconsin Investment Board
40
State of Wisconsin Investment Board
Wisconsin
$370K -$119K -34,900 -22%
Prudential Financial
41
Prudential Financial
New Jersey
$342K -$347K -101,900 -47%
NYLIM
42
New York Life Investment Management
New York
$319K -$57K -16,744 -14%
SO
43
STRS Ohio
Ohio
$302K – – –
Bank of America
44
Bank of America
North Carolina
$289K -$20.7K -6,078 -6%
Dimensional Fund Advisors
45
Dimensional Fund Advisors
Texas
$277K – – –
Connor, Clark & Lunn Investment Management (CC&L)
46
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$273K +$9.58K +2,816 +3%
HF
47
HRT Financial
New York
$213K -$374K -109,927 -61%
Macquarie Group
48
Macquarie Group
Australia
$210K – – –
D.E. Shaw & Co
49
D.E. Shaw & Co
New York
$210K -$45.8K -13,473 -16%
JP Morgan Chase
50
JP Morgan Chase
New York
$205K +$18.7K +5,500 +9%
1
2
3 4 5

AVIR Hedge Fund Activity: Q3 2023 in Review

119 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q3 2023, worth a combined $171M — down 20% from $213M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of AVIR and 6 opened new positions — a net loss of 14 holders — while 42 trimmed existing stakes and 44 added.

The largest buyer was BML Capital Management, adding an estimated $8.72M. The largest seller was Fidelity Investments, cutting an estimated $6.96M.

  • 119 institutional investors held Atea Pharmaceuticals (AVIR) as of Q3 2023, down from 133 in Q2 2023.
  • Funds reported $171M of Atea Pharmaceuticals stock for Q3 2023, down 20% quarter-over-quarter.
  • 6 funds opened new Atea Pharmaceuticals positions in Q3 2023 and 20 closed out, a net change of -14 holders.
  • The largest Atea Pharmaceuticals buyer in Q3 2023 was BML Capital Management, an estimated $8.72M added.
  • The largest Atea Pharmaceuticals seller in Q3 2023 was Fidelity Investments, an estimated $6.96M sold.

Based on aggregated 13F filings for Q3 2023.